← Back to patent-cliff list
HTMC-0435
Tier C — Watch / tradeHTMC-0435
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PARP1, PARP-2
Indications (approved)：Biliary tract cancer, Pancreatic cancer, Small cell lung cancer, Solid tumour, Castration-resistant prostate cancer, Ovarian cancer, Prostate cancer
Regional status
US
Phase I
2022-06-20
EU
-
China
Phase II
2020-05-27
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HTMC-0435?
Approved indications include: Biliary tract cancer, Pancreatic cancer, Small cell lung cancer, Solid tumour, Castration-resistant prostate cancer, Ovarian cancer, Prostate cancer.
When does the HTMC-0435 patent expire?
No public expiry year is available for HTMC-0435 yet; this page updates once verified.
How do I get a quote for HTMC-0435 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07